-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を2ドル引き下げ、29ドルとします。これにより、IVZ株は、2027年調整後EPS予想3.05ドルの9.5倍、2026年EPS予想2.65ドル（本日0.05ドル引き下げ）の10.9倍で評価されます。これは、1年先の平均予想PER10倍、同業他社平均PER16倍と比較して高い水準です。インベスコは、2026年第1四半期の調整後EPSが0.57ドルとなり、当社の予想0.62ドルには届きませんでしたが、市場コンセンサスの0.58ドルに近い水準でした。また、218億ドルの純長期資金流入を記録し、11四半期連続のプラス成長を達成しました。 QQQの転換によるメリットと平均運用資産残高の増加により、投資運用手数料は前年同期比25.6%増の13億8000万ドルに急増しましたが、QQQの構造変更によりサービス手数料は18.6%減少しました。当社は、QQQの転換が予想通りに実現し、収益成長に大きく貢献するとともに、IVZが主力商品からより多くの手数料収入を獲得できる能力を示していると見ています。現在、当社の2026年EPS予想の9.7倍で取引されており、配当利回りは3.3%であることから、株価は割安であると考えています。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Cincinnati Financial Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price by $7 to $185, valuing CINF shares (currently yielding 2%) at 20x our 2027 operating EPS estimate of $9.15 (raised by $0.10) and at 21.5x our 2026 EPS estimate of $8.60 (raised by $0.10), versus its five-year average forward multiple of 21x and peer average. CINF posted Q1 operating EPS of $2.10 versus a $0.24 operating loss per share a year ago, matching our estimate and topping the $1.94 consensus view, amid 12% higher operating revenues due to 11% premium growth and 14% higher net investment income, with written premium growth of 7% likely at the upper end of peer averages. We believe CINF's competitive strengths include its facile underwriting style and ability to allocate underwriting capital to areas with the most promising fundamentals, positioning it well despite increasingly competitive market conditions. CINF's ability to consistently produce above-peer growth and underwriting profitability will support the shares' premium valuation versus peers, in our view.
$CINF
Research
Research Alert: CFRA Maintains Hold Opinion On Shares Of Linde Plc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $48 to $537, using a P/E of 27.1x, equal to LIN's average forward P/E over the last three years. We raise our 2026 EPS estimate by $0.05 to $18.03 and 2027 by $0.26 to $19.81. LIN reported Q1 adj. EPS of $4.33, beating consensus by $0.06, with 30% operating margins and 24% ROC demonstrating the resilience of its business model. Management raised the low end of full-year guidance to $17.60-$17.90 (7%-9% growth), citing confidence despite geopolitical headwinds. The $7.1B project backlog should reach $8B+ by year-end, driven by Electronics projects supporting AI chip manufacturing. Americas volumes grew 2% Y/Y with double-digit hardgoods growth, though EMEA remains challenged by weak industrial activity. Commercial space is emerging as a significant growth driver, with aerospace sales up double-digits. Helium supply tightness presents upside opportunity beyond guidance. We think shares are fully valued at 25.6x our 2027 EPS estimate, limiting upside potential in the near term.
$LIN
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Silgan Holdings Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $13 to $46, based on an EV/EBITDA of 8.9x our 2026 EBITDA estimate, in line with SLGN's three-year average multiple. We increase our 2026 EPS estimate by $0.05 to $3.90 and raise 2027's by $0.05 to $4.20. Metal containers started the year strong, up 2% Y/Y, with pet food product volume up 11%. Management continues to see a long runway for growth in the fragrance, beauty, and health care category now that it is fully integrated into the Weener portfolio. We anticipate further product launches and customer partnerships in 2027, driving growth in this space. Dispensing and specialty closures headwinds are due to higher-cost inventory with volumes adversely affected by severe weather events in North America. Management also noted that volume is likely to improve in 2H 2026 after securing new business wins that have yet to be commercialized but were secured earlier this year.
$SLGN